Investor-to-state dispute settlement’ in EU–US trade deal risks access to affordable medicines

Several European and American health NGOs publicly criticised the inclusion of investor-to-state-dispute-settlement (ISDS) in the Transatlantic Trade and Investment Partnership (TTIP) today, warning that it will undermine public health policies of European Union (EU) Member States and severely jeopardise access to affordable medicines and public health protection.

Joint Response to the European Commission Consultation on the Investor to State Dispute Mechanism (ISDS) in the Transatlantic Trade and Investement Partnership  (TTIP), by Commons Network, HAI, Health GAP, KEI Europe, Salud por Derecho, ISDB, UAEM  and Medicines in Europe Forum: UAEM

 

ISDS Consultation Response 

Press Release:

Press-release-Joint-response-ISDS-in-TTIP 

Posted in Europe, IP, TTIP